U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease

The U.S. Food and Drug Administration has approved a groundbreaking drug for pancreatic cancer, a notoriously difficult disease to treat. The medication, dubbed daraxonib and sold under the brand name Rasonque, operates as a two-pill-per-day regimen and extends the lives of patients with metastatic pancreatic cancer. Pancreatic cancer is notorious for its resistance to traditional treatments, such as chemotherapy, especially in later stages.

A phase 3 clinical trial involving 500 patients, many of whom had specific gene mutations and had undergone prior chemotherapy, revealed that those prescribed daraxonib lived an average of 13.2 months, compared to 6.6 months for the chemotherapy group. This breakthrough demonstrates the potential for targeted treatments in pancreatic cancer, with the possibility of eliminating the need for chemotherapy in certain cases.